Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalation of Pegasys in CHC Non-responders
NCT02791256Phase 3Terminated
- Sponsor
- Roche
- Start
- Jun 2005
- Primary completion
- Jun 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfa-2a in hepatitis C (HCV), sponsored by Roche. Started Jun 2005; status: terminated.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02791256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791256.